Latest News - GrayBug

Monday, December 11, 2017 | Management/Leadership, GrayBug

Graybug Vision Expands Executive Leadership Team

Graybug Vision announced the addition of four key members to its leadership team as it continues to advance its ocular treatments through clinical development and evolve into a commercial biotech comp…

Read the full story

Tuesday, September 19, 2017 | Clinical Trials, Retina, AMD, GrayBug

Graybug Vision Initiates Phase 1/2 Trial of GB-102 for Wet AMD

Graybug Vision announced that it has begun dosing patients with wet AMD in its first clinical trial of GB-102, its lead product. GB-102 is a novel intravitreal (IVT) injectable depot formulation of su…

Read the full story

Tuesday, January 03, 2017 | Management/Leadership, GrayBug

Graybug Vision Appoints Thomas S. Templeman, PhD, as Chief Operating Officer

Graybug Vision announced that Thomas S. Templeman, PhD, has joined the company as chief operating officer. In this new position, Dr. Templeman reports to Graybug Vision Chief Executive Officer Jeffrey…

Read the full story

Thursday, May 05, 2016 | Clinical Trials, Conferences, GrayBug

Graybug Vision GB-102 Toxicology/PK Study Presented at ARVO 2016

Graybug Vision announced that a second poster with new data from a preclinical study of its lead product, GB-102, a novel injectable depot formulation containing a compound blocking VEGF and PDGF rece…

Read the full story

Tuesday, May 03, 2016 | Clinical Trials, GrayBug

Graybug Vision Presents Data for Preclinical AMD Treatment Candidate at ARVO 2016

Graybug Vision announced that data from a preclinical study of its lead product, GB-102, a novel injectable depot formulation containing a compound blocking VEGF and PDGF receptors for twice-a-year tr…

Read the full story

Wednesday, August 05, 2015 | Partnerships, Aerie Pharmaceuticals, GrayBug

Aerie Pharmaceuticals and GrayBug Announce Research Collaboration

Aerie Pharmaceuticals and GrayBug announced a research collaboration and license agreement to deliver some of Aerie’s preclinical product candidates to both the front and back of the eye using G…

Read the full story

Thursday, May 21, 2015 | Management/Leadership, GrayBug

GrayBug Announces Leadership Transition

GrayBug announced that Jeffrey L. Cleland, PhD, will assume the role of interim chief executive officer, according to a company news release. Christy Shaffer, PhD, managing director of Hatteras Discov…

Read the full story